Cargando…
Moderate and severe plaque psoriasis: cost-of-illness study in Italy
Psoriasis is a chronic inflammatory, immune-mediated skin disorder that affects 1.5–1.8 million people in Italy. The most common form of the disease is chronic plaque psoriasis, affecting about 90% of psoriasis patients, with about 20%–30% of them suffering from a moderate or severe condition. Littl...
Autores principales: | Colombo, GL, Altomare, GF, Peris, K, Martini, P, Quarta, G, Congedo, M, Costanzo, A, Di Cesare, A, Lapucci, E, Chimenti, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504078/ https://www.ncbi.nlm.nih.gov/pubmed/18728854 |
Ejemplares similares
-
A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
por: Colombo, Giorgio L, et al.
Publicado: (2009) -
The Cost Effectiveness of Biologic Therapy for the Treatment of Chronic Plaque Psoriasis in Real Practice Settings in Italy
por: Spandonaro, Federico, et al.
Publicado: (2014) -
Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy
por: Ravasio, Roberto, et al.
Publicado: (2021) -
The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis
por: Nyholm, Nanna, et al.
Publicado: (2023) -
Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
por: Hendrix, Nathaniel, et al.
Publicado: (2018)